NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

Which drug has been shown to decrease mortality in non-responders of vasoreactivity testing for PAH?

IV epoprostenol
Diltiazem
Ambrisentan
Riociguat

The correct answer is: IV epoprostenol

Sorry, I accidentally included the word "Explanation" in my previous response. Here is a better explanation One of the main treatment options for pulmonary arterial hypertension (PAH) is vasodilator therapy. This involves administering medications that relax the blood vessels in the lungs, improving blood flow and reducing the workload on the heart. However, not all patients with PAH respond well to this type of therapy. In these cases, IV epoprostenol (also known as prostacyclin) has been shown to decrease mortality rates in non-responders of vasoreactivity testing. This option is preferred over the other choices, as diltiazem is a calcium channel blocker that may worsen symptoms in PAH patients, ambrisentan is a selective endothelin receptor antagonist with less evidence supporting its use in non-responders, and riociguat is a newer medication with limited studies in this population.